Literature DB >> 11403264

Detection of macroprolactinemia with the polyethylene glycol precipitation test in systemic lupus erythematosus patients with hyperprolactinemia.

A Leaños-Miranda1, D Pascoe-Lira, K A Chávez-Rueda, F Blanco-Favela.   

Abstract

The objective of this study was to determine the diagnostic performance of the percentage of serum prolactin (PRL) precipitated with polyethylene glycol (PEG) for the detection of macroprolactinemia in systemic lupus erythematosus (SLE) patients with hyperprolactinemia. Serum samples from SLE patients were examined. Serum PRL was measured by immunoradiometric assay (IRMA) and samples with hyperprolactinemia (> 20 ng/ml) were submitted to PEG precipitation, gel filtration chromatography and affinity chromatography with protein-G sepharose. A comparative survey was used. Among 259 consecutive serum samples from SLE patients, PRL was > 20.1 ng/ml in 43 samples (16.6%). Gel filtration showed a predominant pattern of macroprolactinemia (> 100 kDa) in 14 (32.6%), a predominant pattern of monomeric PRL (23 kDa) in 27 (62.7%), and a variable pattern in two (4.7%). All sera with a predominant pattern of macroprolactinemia displayed anti-PRL autoantibodies by affinity chromatography for IgG. The best cut-off point for percentage of serum PRL precipitated with PEG for detection of macroprolactinemia was > or = 58.4%. Sensitivity and specificity were 100 and 96.6%, respectively. We can conclude that PEG precipitation is a convenient and simple procedure to screen for the presence of macroprolactinemia in sera from SLE patients. Precipitations > or = 58.4% are indicative of the presence of, and those < 50% the absence of, macroprolactinemia. However, samples with precipitations between 50 and 58.3% require gel filtration chromatography to characterize the predominant molecular form of PRL. Therefore, it is important to take these findings into account in future studies that aim to establish a relationship between PRL and disease activity in SLE.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11403264     DOI: 10.1191/096120301672772070

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  8 in total

1.  Prolactin may not play a role in primary antiphospholipid (Hughes') syndrome.

Authors:  Manoel Tavares Neves Junior; Carlos Ewerton Maia Rodrigues; Jozelio Freire de Carvalho
Journal:  Clin Dev Immunol       Date:  2011-04-07

2.  Identification of IgG-immunocomplex macroprolactin with an immunometric "sandwich" system: technical and clinical considerations.

Authors:  P Amadori; C Dilberis; A Marcolla; M Pinamonti; P Menapace; A Valentini
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

3.  Macroprolactinemia: the consequences of a laboratory pitfall.

Authors:  Erzsébet Toldy; Zoltán Löcsei; István Szabolcs; Miklós I Góth; Pál Kneffel; Dominika Szöke; Gábor L Kovács
Journal:  Endocrine       Date:  2003-12       Impact factor: 3.633

4.  Antiprolactin autoantibodies are associated with hyperprolactinemic status in men infected with human immunodeficiency virus.

Authors:  Alfredo Leaños-Miranda; Iris Contreras-Hernández
Journal:  Endocrine       Date:  2002-11       Impact factor: 3.925

Review 5.  Global Prevalence of Macroprolactinemia among Patients with Hyperprolactinemia: A Systematic Review and Meta-Analysis.

Authors:  Noor Azlin Azraini Che Soh; Najib Majdi Yaacob; Julia Omar; Aniza Mohammed Jelani; Noorazliyana Shafii; Tuan Salwani Tuan Ismail; Wan Norlina Wan Azman; Anis Kausar Ghazali
Journal:  Int J Environ Res Public Health       Date:  2020-11-06       Impact factor: 3.390

6.  Prevalence of Macroprolactinemia in People Detected to Have Hyperprolactinemia.

Authors:  Lokesh Kumar Sharma; Deep Dutta; Neera Sharma; Bindu Kulshreshtha; Sandhya Lal; Ritika Sethi
Journal:  J Lab Physicians       Date:  2021-07-12

Review 7.  Macroprolactinemia: diagnostic, clinical, and pathogenic significance.

Authors:  Akira Shimatsu; Naoki Hattori
Journal:  Clin Dev Immunol       Date:  2012-12-04

8.  Frequency of Macroprolactinemia in Hyperprolactinemic Women Presenting with Menstrual Irregularities, Galactorrhea, and/or Infertility: Etiology and Clinical Manifestations.

Authors:  Alfredo Leaños-Miranda; Karla Leticia Ramírez-Valenzuela; Inova Campos-Galicia; Rosario Chang-Verdugo; Lizbeth Zarela Chinolla-Arellano
Journal:  Int J Endocrinol       Date:  2013-09-30       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.